71 results about "Gonadal hormones" patented technology

A complex is provided for the treatment of neurogenic conditions having the formula:where R1 isM is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, L-lactate, L-leucine, L-tryptophan, and L-glutamate; and R is coupled to M through a carboxylate moiety. Magnesium(II) represents the preferred metal ion as magnesium is known to have neuroprotective effects. The metal ion is in part chelated by a non-steroidal anti-inflammatory drug that does not inhibit platelet activity and includes salicylate and ibuprofenate. The complex also includes a ligand operative in transport across the blood brain barrier. A process for making an inventive complex includes the stoichiometric addition of ligands containing carboxylate groups to a solution of the metal ion. In instances where the metal ion is magnesium(II), a stoichiometric ratio of 1:1:1 is found between the non-steroidal anti-inflammatory ligand:magnesium(II):transporter ligand.

A compound of the formulawhere R1 is H, C1–C4 alkyl and OH; R2 in is H, C1–C4 alkyl and OH; R3 is H and C1–C4 alkyl; R4 is H and C1–C4 alkyl; n is an integer between 0 and 2 inclusive; R5 is a nullity, NHR7C(O)—, C6H4—, C6H4—O—; R7 is C2–C6 alkyl; and R6 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, transferrin, glucosylamine, amino saccharin, saccharin ester, lactylamine, leucine, tryptophan, amino glutamate and amino cholines.

The invention relates to a method for analyzing the content of ginsenoside in a ten-ingredient Xiangdeer capsule, and belongs to the technical field of traditional Chinese medicine formulae. The ten-ingredient Xiangdeer capsule gives full play to the value of each traditional Chinese medicine, and has the effects of soothing liver-qi stagnation, softening hardness to dissipate stagnation and the like. The pharmacodynamic material basis of the ginseng is ginsenoside, and the ginsenoside has an adjusting effect on the neuroendocrine function of the pituitary-gonad axis; the ginsenoside can excite pituitary to secrete gonadotropin, promote biosynthesis of DNA and protein synthesis related zymoprotein, increase gonad activity, and balance positive and negative feedback functions of neuroendocrine through a bidirectional regulation effect on pituitary-gonad axis so as to achieve the purpose of reducing estradiol which is abnormally increased. Mammary gland cell proliferation controlled by ovarian hormones is inhibited. According to the method, the internal components of the traditional Chinese medicine are selected as internal standards by adopting a quantitative analysis of multi-components by single marker, and the content of the components to be detected is calculated by measuring the relative correction factor RCF between the traditional Chinese medicine and other components to be detected, so that the use amount of reference substances is reduced, and the cost is saved.